Utipro® Plus Launched In France

We are pleased to announce the launch in France of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is commercialized over the French territory under the umbrella…

New scientific publication on Mucoprotection and diarrheal processes.

Expert Opin Investig Drugs. 2017 Dec 26:1-6.

 

NO ABSTRACT AVAILABLE

…

Corporate Press Release: Noventure and Laboratorios Salvat enter into agreement to commercialise innovative medical device in Spain and Portugal for rhinitis and rhinosinusitis

Barcelona, Spain, February 22, 2018 - Noventure and Laboratorios Salvat, S.A. (Salvat), announce today that they have entered into an agreement in which Salvat will distribute…

Noventure welcomes new partners to expand the presence of its products in new territories.

We are pleased to announce that we are expanding the international coverage of our products thanks to the recent signature of agreements with both new and loyal partners.  These new…

Noventure is delighted to announce the launch of Tasectan® in Russia by its partner company Jadran, under the umbrella brand Adiarin®

Adiarin®  is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia.

Tasectan® in Europe is a class III medical…

Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually.

Health Aff (Millwood) 2018 Apr;37(4):662-669. doi: 10.1377/hlthaff.2017.1153. Epub 2018 Mar 21.

Abstract…